These results are consistent with those of previous reports,12, 13, 14, 15 suggesting that although the effect of immunotherapy on chemotherapy may be limited for patients with advanced NSCLC and high PD‐L1 expression, COMB treatment should be considered as an option in cases of good PS. This evidence concerns the gene CD274 and non-small cell lung carcinoma.